SecBot SecBot

GH

Guardant Health, Inc.
Nasdaq· Services-Medical Laboratories· Inc. DE· CIK 0001576280 Healthcare & Medical Devices
$144.03 −7.67 (−5.06%)
Nov 16 4:00 PM ET · prev $151.70
Market cap
$21.0B
Large cap
Consensus
Buy
92% Buy or better · 36 analysts
Median target
$200.00
+39% · range $105.00–240.00
1 year
+49.3%
from $96.48 · Nov 17
30 days
−8.8%
from $157.88
52-week range
$78.60–187.22
−23% from high · low Apr 10
Avg volume 20D
2.29M
shares / day
Short interest
9.43M
≈7.0% of shares · −19.2%
Days to cover
5.4
at average volume
Insider net
−$243.0K
0 buyers · 3 sellers · since Sep 16
New fund stakes
4
Q3 2026 13F · 1 exit
Filing reports
38
analyzed by SecBot
SecBot read MIXED 13 reports · 90 days
Balance 2 bearish · 1 bullish · 10 neutral oldest → newest, height = score
Avg score ·High conf. 9/13

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $243.0K.

  • InstitutionsBULLISH

    Q3 2026: 55 added (4 new), 28 trimmed or exited. Largest new: Agf Management $201.8M, Nomura Asset Management $28.8M.

  • AnalystsBULLISH

    33 of 36 rate it Buy or better. Median target $200.00 (+39%).

  • Short sellersCOVERING

    Short interest −19.2% to 9.43M shares. 5.4 days to cover, ≈7.0% of shares.

  • TrendDOWNTREND

    14% below its 50-day average.

Who's buying

13F· Q3 2026
4
new positions
1
exit
$251.4M
in new stakes · top 3 shown
FundMoveSharesValue
FMR LLCADD7,342,273$1.3B
Invesco Ltd.TRIM2,974,224$530.5M
FULLER & THALER ASSET MANAGEMENT, INC.TRIM1,698,874$303.0M
Qube Research & Technologies LtdDOUBLED1,306,069$233.0M
UBS Group AGADD1,149,570$205.0M
AGF MANAGEMENT LTDNEW1,131,513$201.8M
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLCTRIM937,974$167.3M
MANUFACTURERS LIFE INSURANCE COMPANY, THETRIM912,063$162.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

36 analysts
Buy 92% rate it Buy or better
Strong Buy15Buy18Hold3Sell0Strong Sell0
12-month targets · 25 analysts

Price is inside the target range. Median implies +39%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 10, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight
Oct 27, 2026BTIG
MAINTAIN
MAINTAINBuy
Oct 23, 2026Roth Capital
INITIATE
INITIATEBuy
Oct 13, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Oct 7, 2026Barclays
MAINTAIN
MAINTAINOverweight
Oct 1, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Congressional trades
GH trades disclosed by members of Congress, with disclosure delay.
1 members · 1 buys / 0 sells
DateMemberType AmountDisclosed
Sep 28, 2026 Jonathan JacksonDHouse Joint account · Guardant Health Inc BUY $15K–$50K Oct 19, 2026 +21d

Insider ledger

Form 4
$0
bought · 0 insiders
$243.0K
sold · 3 insiders
DateInsiderTypeValue
Nov 12, 2026
Azar Alex M II
Director
Nov 12, 2026
EXERCISE138 sh
Nov 9, 2026
PARKS ROBERT
Chief Accounting Officer
Nov 9, 2026
AWARD18,893 sh
Nov 9, 2026
SAYER KEVIN R
Director
Nov 9, 2026
AWARD3,149 sh
Oct 21, 2026
MIGNONE ROBERTO
Director
Oct 21, 2026
EXERCISE264 sh
Oct 17, 2026
Hidalgo Medina Manuel
Director
Oct 17, 2026
EXERCISE232 sh
Oct 16, 2026
Tariq Musa
Director
Oct 16, 2026
SELL$19.2K
Oct 15, 2026
Tariq Musa
Director
Oct 15, 2026
EXERCISE250 sh
Oct 14, 2026
Azar Alex M II
Director
Oct 14, 2026
SELL$11.0K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

36 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
9,433,137
shares short
-19.2%
vs prior settlement
5.4
days to cover
≈7.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 SEC
Kevin R. Sayer filed a Form 3 initial statement of beneficial ownership with the SEC, reporting zero shares of…
3 · Impact 1/10
Nov 12, 2026 SEC
Robert Parks filed a Form 3 initial statement of beneficial ownership with the SEC, reporting zero shares of Guardant…
3 · Impact 2/10
Nov 12, 2026 Insider
Azar Alex M II acquired via exercise 138 shares
Director
Nov 9, 2026 Insider
PARKS ROBERT was granted 18,893 shares
Chief Accounting Officer
Nov 9, 2026 Insider
SAYER KEVIN R was granted 3,149 shares
Director
Nov 5, 2026 Earnings result
GH Q3 2026 Earnings: EPS $-0.29 (+10.9% vs est)
Sep 30, 2026 Inst.
FMR LLC · ADD
7,342,273 shares ($1.3B)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 5, 2026
Earnings result
GH Q3 2026 Earnings: EPS $-0.29 (+10.9% vs est)
Jul 30, 2026
Earnings date
GH Q2 2026 Earnings After Market Close, 2026-07-30
Jun 16, 2026
Enforcement
TwinStrand Biosciences, Inc. & University of Washington v. Guardant Health, Inc.
Court ruling from District Court, D. Delaware. Docket: 1:21-cv-01126
May 27, 2026
Enforcement
Cold Spring Harbor Laboratory v. Guardant Health, Inc.
Court ruling from District Court, D. Delaware. Docket: 1:25-cv-00263
May 13, 2026
Short interest
FTD: GH, 65,529 shares ($6.5M) failed to deliver
Settlement: 20260513, Price: $99.94, FTD Value: $6,548,968.26, GUARDANT HEALTH INC COM

SecBot reports

38 filings · 2 bullish · 5 bearish · 31 neutral
All GH filing & press-release reports (38)